Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study With Orally Administered CVM-1118 and Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT03582618 is registered in ClinicalTrials.gov with TaiRx, Inc. as lead sponsor.

NCT NCT03582618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03582618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study With Orally Administered CVM-1118 and Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
TaiRx, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 12, 2018
Completion date
December 30, 2022
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, hepatocellular carcinoma